APA (7th ed.) Citation

Bauhammer, J. S., Blank, N., Max, R., Lorenz, H., Wagner, U., Krause, D. M. J., & Fiehn, C. (2016). Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: Anti-Ro52 positivity as a marker for severity and treatment response. The journal of rheumatology, 43(8), . https://doi.org/10.3899/jrheum.150844

Chicago Style (17th ed.) Citation

Bauhammer, Jutta Sinikka, Norbert Blank, Regina Max, Hanns-Martin Lorenz, Ulrich Wagner, Dietmar Michael Josef Krause, and Christoph Fiehn. "Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response." The Journal of Rheumatology 43, no. 8 (2016). https://doi.org/10.3899/jrheum.150844.

MLA (9th ed.) Citation

Bauhammer, Jutta Sinikka, et al. "Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response." The Journal of Rheumatology, vol. 43, no. 8, 2016, https://doi.org/10.3899/jrheum.150844.